ag真人平台官方

　　EGFR检测适用人群

　　根据现有临床数据,对符合条件的转移性NSCLC患者应当进行EGFR检测,其中包含有常见突变及罕见突变。同时,NCCN专家建议对符合条件的的可切除IB至IIIA期NSCLC患者进行 EGFR突变的分子检测，以确定是否可以选择使用奥希替尼进行辅助治疗。

　　EGFR检测与TKI药物

　　EGFR 19号外显子缺失和21号外显子突变 (L858R)是NSCLC患者中最常见的突变,这两种突变分别占所有突变患者的45%和40%。两种突变都会导致酪氨酸激酶结构域的激活, 并与小分子 EGFR TKI 药物的敏感性有关，例如厄洛替尼、吉非替尼、阿法替尼、奥希替尼和达克替尼^[12]。在以前,这些突变常被表述为敏感性突变,但现在更多的特殊突变被人们发现。这些常见的 EGFR 突变存在于大约 10% 的非小细胞肺癌白种人患者和高达 50% 的亚洲患者中^[13]。其他不太常见的突变（约 10%）也对 EGFR TKI 敏感，包括exon 19 插入, p.S768I, p.L861Q和p.G719X^[14,15]。目前的证据表明,对于没有这些特异性EGFR 突变的肿瘤患者,不应在任何治疗方案中使用 EGFR TKI 进行治疗。

　　图片来源: Riely GJ, Clin Cancer Res, 2006 Dec 15.

　　绝大多数具有常见 EGFR 突变的腺癌患者是不吸烟者或轻度吸烟者。有数据表明，腺鳞癌患者也可发生 EGFR 突变，但腺鳞癌在小标本中很难与鳞状细胞癌区分[16]。单纯的鳞状细胞癌患者不太可能出现常见的 EGFR 突变；但那些患有腺鳞癌的人可能会有突变[3,4,16] 。尽管如此,吸烟状况、种族和组织学类型都不应当作为选择检测人群的标准。尽管发生率低于转移性 NSCLC 腺癌患者[2,3,4,8,9], NCCN 的专家组仍然建议对所有转移性 NSCLC 鳞状细胞癌患者进行分子检测，因为这些患者也可能具有临床意义的生物标志物变异，例如 EGFR 突变。

　　EGFR 19 号外显子缺失和 L858R 突变预测TKI药物疗效的作用已被确认。具有这些常见 EGFR 突变的患者对阿法替尼、达克替尼、厄洛替尼、吉非替尼或奥希替尼的反应明显更好^[12]。目前的临床实验数据表明, EGFR TKI 疗法作为晚期 NSCLC 中常见 EGFR 突变患者的一线单药治疗是有效的。与细胞毒性的全身治疗(化疗)相比，使用 EGFR TKI 单药治疗携带EGFR 突变的患者,其无进展生存期 (PFS) 更长,但阿法替尼、厄洛替尼、吉非替尼的总生存期没有统计学差异^{[17,18,23,24]}。对 EGFR TKI 治疗无反应则与 KRAS 和 BRAF 突变以及 ALK 或 ROS1 基因重排有关。另外,EGFR 外显子 20 插入突变的患者通常对厄洛替尼、吉非替尼、阿法替尼或达克替尼耐药，但也有罕见的例外（例如，p.A763_Y764insFQEA）。患者通常会在一线 EGFR TKI 单一疗法治疗后出现疾病的进展(耐药) 。

　　EGFR TKI的耐药

　　当大多数普通EGFR突变患者对阿法替尼、厄洛替尼或吉非替尼产生耐药性时,其PFS为9.7至13个月^{[18,24,27-29]}。EGFR p.Thr790Met (T790M) 是一种与 EGFR TKI 治疗相关的获得性耐药突变，据报道,约 60%在对厄洛替尼、吉非替尼、吉非替尼、或阿法替尼初始敏感的患者,其发生耐药后会出现T790M突变^[10,29-35]。有研究表明，T790M很少发生在以前从未接受过厄洛替尼、吉非替尼或阿法替尼治疗的患者中^[36]。另外,无论是否吸烟, 基因组上携带 p.T790M 者,都有高风险罹患肺癌^[37-39]。 因此,如果在治疗前就发现了T790M突变,则建议患者进行遗传咨询。对 EGFR TKI 的获得性耐药也可能与患者从 NSCLC 到 SCLC 的组织学转化以及上皮到间质转化有关^[40-44]。专家们建议在疾病进展时可以考虑进行活检以排除 SCLC 转化并评估其耐药机制[41]。最后,获得性耐药也可由其它分子事件介导,如ALK重排,MET或ERBB2扩增等^[45]。

　　图片来源: Yu HA, Clin Cancer Res. 2013 Apr 15.

　　综上,基于阿法替尼、达科米替尼、埃洛替尼、吉非替尼和奥西替尼疗效的数据[1,17-22],专家组建议对转移性非鳞状细胞肺癌或非特指型NSCLC患者的EGFR突变状态和其他生物标志物进行检测。同时,如前所述,鳞状细胞癌的患者也可以进行同样的检测。

　　EGFR的检测方法

　　DNA突变分析被用于评估EGFR状态,IHC则不建议用于检测EGFR突变^[46-49]。荧光定量PCR、Sanger测序和NGS是常用的检测EGFR技术^[7,46]。直接测序18至21号外显子(或者仅检测19,21号外显子),是一种比较合理的方案;但也有更灵敏的方法^{[13,48,50,51]}。如利用多重PCR进行的突变筛查可以同时检测50多个点突变^[52] 。然而,NGS仍然是检测EGFR变体的首选方法, 因靶向PCR方法可能会漏掉一些EGFR外显子20插入突变^[11]。

　　EGFR突变阳性患者的治疗

　　对于EGFR突变阳性（外显子19缺失，L858R）的转移性NSCLC患者,其一线治疗方案已确认。奥西替尼是EGFR阳性的转移性NSCLC患者首选的一线EGFR TKI选择。埃洛替尼（±贝伐单抗或拉穆昔单抗）、阿法替尼、达科替尼或吉非替尼等是一线EGFR TKI治疗的“其他推荐”选项。
　　而对于EGFR T790M阳性的转移性非小细胞肺癌或埃洛替尼（±贝伐单抗或拉穆昔单抗）、阿法替尼、达科替尼、吉非替尼治疗的疾病进展患者，则推荐奥西替尼作为二线及后续治疗[28,53]。

　　对第一代、第二代和第三代EGFR TKI（如埃洛替尼、阿法替尼、吉非替尼、奥西替尼；经典EGFR TKIs）同样敏感的较不常见的EGFR突变（约10%）包括外显子19插入，p.L861Q、p.G719X和p.S768I[14,15,23,54]。有鉴于阿法替尼或奥西替尼是携带EGFR S768I、L861Q和G719X患者一线治疗方案,推荐对转移性NSCLC患者进行这些位点的检测[23,54]。在此情形中,其它推荐的TKI药物还有埃洛替尼、吉非替尼或达科米替尼^[55,56]。

　　EGFR外显子20插入突变

　　20号外显子插入突变是第三种常见的EGFR突变, 它们发生在约2%的NSCLC患者和4%至12%的EGFR突变患者中^[6,26,57,58]。尽管有许多不同的EGFR外显子20插入突变，但这三种（insASV、insSVD和insNPH）最为常见[6]。大多数EGFR外显子20插入突变患者对埃洛替尼、阿法替尼或吉非替尼的应答率较低（≤9%）^[5,6]。但p.A763_Y764insFQEA突变是个例外, 埃洛替尼、阿法替尼或吉非替尼对这个EGFR 20外显子插入突变的患者有效^[25]。

　　当以高剂量（160 mg/天）使用时，奥西替尼对EGFR 20外显子插入突变的患者应答率约为25%，这远低于EGFR外显子19缺失或L858R突变携带者^[59]。一线铂类化疗（±免疫疗法）是EGFR 20外显子突变患者的推荐疗法^[60-62]。与接受厄洛替尼、阿法替尼或吉非替尼靶向治疗（约39个月）的EGFR外显子19缺失或L858R突变患者相比,接受一线铂类治疗的EGFR 20外显子插入突变的患者的中位总生存期较短（约16个月）^[5,63,64]。其免疫治疗的应答率(0-25%)则取决于不同的EGFR 20外显子插入种类^[6,65,66]。

　　有鉴于amivantamab-vmjw(JNJ-6732)和莫博塞替尼(TAK788)在后线治疗EGFR 20外显子插入突变患者的数据,NCCN专家们推荐在转移性NSCLC患者中进行EGFR 20外显子插入突变的检测[5,6]。NGS是检测EGFR 20插入突变的首选,PCR策略则会漏掉一些变异。

　　图片来源;Zhou C, JAMA Oncol. 2021 Dec 1

　　华测肺癌个性化用药

　　对肺癌常见的 52 个热点突变基因进行高深度测序，覆盖国内外 FDA/NMPA 批准上市、NCCN 指 南推荐，以及在临床试验阶段的 279 种靶向药物;同时提供 lynch 综合症相关 EPCAM、MLH1、MSH2、 MSH6、PMS2 等 MMR 基因的致病突变解读，以及基于万人级别药物基因组数据的 PharmGKB 数据 库中肿瘤常用 38 种化疗药物疗效及毒副作用评估结果，适用于初诊患者的全面靶点检测和药物筛选，同时对于复发转移、多发耐药的肺癌患者提供跨适应症用药、治疗方案更换的分子依据。

　　参考文献
　　[1] Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med 2020;382:41-50.
　　[2] Ettinger DS, Wood DE, Aisner DL, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines?) for Non Small Cell Lung Cancer (Version 4.2022).
　　[3] Lam VK, Tran HT, Banks KC, et al. Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations. Clin Lung Cancer 2019;20:30-36 e33.
　　[4] Sands JM, Nguyen T, Shivdasani P, et al. Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. Lung Cancer 2020;140:35-41.
　　[5] Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol 2021;39:3391-3402.
　　[6] Zhou C, Ramalingam SS, Kim TM, et al. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. JAMA Oncol 2021;7:e214761.
　　[7] Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8:823-859.
　　[8] Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 2019;30:1321-1328.
　　[9] Sholl LM, Aisner DL, Varella-Garcia M, et al. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol 2015;10:768-777.
　　[10] Yu PP, Vose JM, Hayes DF. Genetic Cancer Susceptibility Testing: Increased Technology, Increased Complexity. J Clin Oncol 2015;33:3533-3534.
　　[11] Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013;31:1039-1049.
　　[12] Langer CJ. Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? J Clin Oncol 2013;31:3303-3306.
　　[13] Hirsch FR, Bunn PA, Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol 2009;10:432-433.
　　[14] Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006;12:7232-7241.
　　[15] O'Kane GM, Bradbury PA, Feld R, et al. Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer 2017;109:137-144.
　　[16] Paik PK, Varghese AM, Sima CS, et al. Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component.
　　[17] Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-3334.
　　[18] Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
　　[19] Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
　　[20] Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
　　[21] Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.
　　[22] Zhou C, Wu YL, Chen G, et al. Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2011;29(Suppl 15):Abstract 7520.
　　[23] Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015;16:141-151.
　　[24] Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
　　[25] Vasconcelos P, Gergis C, Viray H, et al. EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors. JTO Clin Res Rep 2020;1.
　　[26] Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 2013;12:220-229.
　　[27] Nishino M, Cardarella S, Jackman DM, et al. RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. AJR Am J Roentgenol 2013;201:W64-71.
　　[28] Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med 2017;376:629-640.
　　[29] Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240-2247.
　　[30] Riely GJ, Yu HA. EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. Clin Cancer Res 2015;21:2221-2226.
　　[31] Finlay MR, Anderton M, Ashton S, et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem 2014;57:8249-8267.
　　[32] Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013;31:3987-3996.
　　[33] Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
　　[34] Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006;12:5764-5769.
　　[35] Onitsuka T, Uramoto H, Nose N, et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 2010;68:198-203.
　　[36] Rosell R, Molina MA, Costa C, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011;17:1160-1168.
　　[37] Berry DK, Wang X, Michalski ST, et al. Clinical Cohort Analysis of Germline EGFR T790M Demonstrates Penetrance Across Ethnicities and Races, Sexes, and Ages. JCO Precis Oncol 2020;4.
　　[38] Oxnard GR, Miller VA, Robson ME, et al. Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol 2012;7:1049-1052.
　　[39] Gazdar A, Robinson L, Oliver D, et al. Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. J Thorac Oncol 2014;9:456-463.
　　[40] Schoenfeld AJ, Chan JM, Kubota D, et al. Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. Clin Cancer Res 2020;26:2654-2663.
　　[41] Marcoux N, Gettinger SN, O'Kane G, et al. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol 2019;37:278-285.
　　[42] Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
　　[43] Oxnard GR. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer. Arch Pathol Lab Med 2012;136:1205-1209.
　　[44] Suda K, Mizuuchi H, Maehara Y, Mitsudomi T. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny. Cancer Metastasis Rev 2012;31:807-814.
　　[45] Yu HA, Suzawa K, Jordan E, et al. Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clin Cancer Res 2018;24:3108-3118.
　　[46] Sholl LM, Cagle PT, Lindeman NI, et al. Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung; Version: LungBiomarkers 1.3.0.0: College of American Pathologists; 2016.
　　[47] Han SW, Kim TY, Jeon YK, et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 2006;12:2538-2544.
　　[48] Dacic S. EGFR assays in lung cancer. Adv Anat Pathol 2008;15:241-247.
　　[49] Sholl LM, Xiao Y, Joshi V, et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol 2010;133:922-934.
　　[50] Eberhard DA, Giaccone G, Johnson BE, Non-Small-Cell Lung Cancer Working G. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008;26:983-994.
　　[51] Shepherd FA, Tsao MS. Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma. J Clin Oncol 2010;28:903-905.
　　[52] Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010;2:146-158.
　　[53] Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372:1689-1699.
　　[54] Cho JH, Lim SH, An HJ, et al. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). J Clin Oncol 2020;38:488-495.
　　[55] Tu HY, Ke EE, Yang JJ, et al. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. Lung Cancer 2017;114:96-102.
　　[56] Otsuka T, Mori M, Yano Y, et al. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212). Anticancer Res 2015;35:3885-3891.
　　[57] Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. J Thorac Oncol 2018;13:1560-1568.
　　[58] Riely GJ, Neal JW, Camidge DR, et al. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discov 2021;11:1688-1699.
　　[59] Piotrowska Z, Wang Y, Sequist LV, Ramalingam SS. ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions. Journal of Clinical Oncology 2020;38:9513-9513.
　　[60] Chelabi S, Mignard X, Leroy K, et al. EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy. Cancers (Basel) 2021;13.
　　[61] Byeon S, Kim Y, Lim SW, et al. Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea. Cancer Res Treat 2019;51:623-631.
　　[62] Naidoo J, Sima CS, Rodriguez K, et al. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. Cancer 2015;121:3212-3220.
　　[63] Dersarkissian M, Bhak R, Lin H, et al. P2.01-103 Real-World Treatment Patterns and Survival in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations. Journal of Thoracic Oncology 2019;14:S681.
　　[64] Morita C, Yoshida T, Shirasawa M, et al. Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions. Sci Rep 2021;11:18762.
　　[65] Ou S-HI, Lin HM, Hong J-L, et al. Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations. Journal of Clinical Oncology 2021;39:9098-9098.
　　[66] Udagawa H, Matsumoto S, Ohe Y, et al. OA07.03 Clinical Outcome of Non-Small Cell Lung Cancer with EGFR/HER2 Exon 20 Insertions Identified in the LC-SCRUM-Japan. Journal of Thoracic Oncology 2019;14:S224.